Evaluation of the genotoxicity of ginseng leaf extract UG0712

Ji-Young Kim1#, Yu Ri2#, Seon-Gil Do1, Young-Chul Lee3, Sang-Joon Park2*

1Laboratory of Genetic Toxicology, Korea Institute of Toxicology, KRICT, Daejeon, Korea
2Department of Histology, College of Veterinary Medicine, Kyungpook National University, 1370 Sankyuk-dong, Bukgu, Daegu, Korea
3Unigen Inc., Cheonan, Korea

Although ginseng (genus Panax) leaf extract contains high concentrations of bioactive constituents, its effects have been reported in few preclinical studies, and information regarding its toxicity is not sufficient to allow for its clinical use. We evaluated the genotoxicity of UG0712, which is a powdered extract of ginseng leaves. UG0712 did not increase the number of revertant colonies in 4 histidine auxotrophic strains of Salmonella typhimurium (TA100, TA1535, TA98, and TA1537) or in a tryptophan auxotrophic strain of Escherichia coli (WP2uvrA(pKM101)) at any concentration evaluated, either in the absence or presence of the metabolic activation system. There was no significant increase in the number of metaphase cells with structural or numerical aberrations in the UG0712-treated groups compared to the concurrent vehicle control at any dose, regardless of the presence of the metabolic activation system. Oral administration of the extract at doses up to 2,000 mg/kg in male mice did not increase the frequency of micronucleated polychromatic erythrocytes in the bone marrow, and did not result in any significant clinical signs, body weight loss, gross findings, or mortality. These results suggest that UG0712 does not act as a mutagenic or genotoxic material at the concentrations evaluated.

Keywords: UG0712, ginseng leaf extract, bacterial reverse mutation, chromosome aberration, micronucleus

Received 8 July 2014; Revised version received 25 August 2014; Accepted 27 August 2014

Ginseng, especially ginseng root, is a commonly used traditional herbal medicine in East Asian countries including China, Korea, and Japan, for its tonic, adaptogenic, restorative, immunomodulatory, anti-inflammatory, anti-oxidant, anti-aging, and anti-cancer properties [1-4]. Ginseng is also one of the most commonly used dietary supplements in North America [4-6]. The study of ginseng has a long history [1]. The bioactive ingredients found in ginseng include more than 60 ginsenosides, such as Rb1, Rb2, Rb3, Rc, Rd, Re, Rg1, Rg2, and Rg3, as well as polysaccharides, oligopeptides, polyacytlenic alcohols, and fatty acids [1,7,8]. Ginsenosides, which are regarded as the major bioactive constituents of ginseng, have a four-ring, steroid-like structure with sugar moieties [9] and have been shown to produce multiple pharmacological effects [1]. Although the pharmacological effects of ginseng root are well known, its use is limited by its significant cost [4,10]. Other parts of the ginseng plant, such as the berry, stem, and leaf are much cheaper than the root, and the leaf can be harvested every year. Recently, it has been reported that ginseng leaf contains numerous bioactive ingredients in high concentrations that are also found in ginseng root, such as ginsenosides, polysaccharides, triterpenoids, flavonoids, polyacytlenic alcohols, volatile oils, peptides, amino acids, and fatty acids [4,11,12]. The total ginsenoside content in the leaf of American ginseng (Panax quinquefolius) is significantly higher than that in the root and the berry [13]. The major...
ginsenosides found in ginseng leaf are Rd, Re, and Rb2 [13]. Ginseng leaf extract has been shown to exert pharmacological effects in the central nervous system (CNS), the cardiovascular system, and the immune system [4].

Although many studies have reported the therapeutic efficacy of ginseng leaf extract, there is little evidence in the scientific literature on its toxicity, and thus recommendations for the safe use of the extract are not well established. Therefore, in the present study, we report results from a series of standardized, Organisation for Economic Co-operation and Development (OECD)- and Korea Food and Drug Administration (KFDA) guideline-compliant in vitro and in vivo studies that were undertaken to investigate the genotoxicity of ginseng leaf extract UG0712. Assays included the bacterial reverse mutation test, the chromosome aberration test, and the bone marrow micronucleus test.

Materials and Methods

Materials

All positive controls and cofactor ingredients for the preparation of the S9 fraction were obtained from Sigma-Aldrich (St. Louis, MO, USA), and dimethyl sulfoxide (DMSO) was obtained from Merck (USA). The S9 fraction was prepared from male Sprague-Dawley rats treated with Aroclor 1254, which was obtained from Molecular Toxicology Inc. (USA).

Preparation of UG0712

UG0712 was prepared by blending partially hydrolyzed ginseng leaf extract in a manner that led to consistent content of ginsenosides Rd and Rg3. Briefly, ginseng leaf extract purchased from Hongju Biotech Co., Ltd. (Yanbian, China) was hydrolyzed under acidic conditions. UG0712 was standardized to contain greater than 5% ginsenoside Rd, greater than 10% ginsenoside Rg3 derivatives (Rg3, Rg5, and Rk1).

The appropriate amount of UG0712 for the highest dose was weighed and added to tubes containing pure DMSO or 0.5% DMSO for the bacterial reverse mutation test and the in vitro chromosome aberration test, respectively, and mixed with a vortexer until it was dissolved. The formulation was serially diluted with the appropriate DMSO vehicle to produce a series of lower doses that were separated by a geometric ratio of 2. The preparation of UG0712 formulations for injection in the in vivo micronucleus test was performed for each dose using water (Choongwae Pharma Corp.).

Bacterial reverse mutation test

The bacterial reverse mutation test was performed using the methods (pre-incubation) described in the OECD and KFDA guidelines [14,15] by Maron and Ames [16] with minor modification. The mutagenic potential of UG0712 was examined in the absence and presence of a metabolic activation system using histidine-requiring Salmonella typhimurium TA98, TA100, TA1535, and TA1537 strains and the tryptophan-requiring Escherichia coli WP2uvrA (pKM101) strain. All strains were purchased from Molecular Toxicology Inc. (Boone, NC, USA). The specific genotype characteristics of the S. typhimurium strains were evaluated, including their histidine requirement, the presence of the uvrB mutation, presence of R-factor, presence of the rfa mutation, and the number of spontaneous revertants. In the case of E. coli, the tryptophan requirement, the presence of the uvrA mutation, and the number of spontaneous revertants were tested according to the methods of Maron and Ames [16]. The viable cell counts in the bacterial cultures used in the test were greater than 1×10⁹ cells per mL.

The dose range-finding test was carried out at 5 concentration levels (312.5, 625, 1,250, 2,500, and 5,000 µg/plate) in vehicle and strain-specific positive controls in the absence and presence of the metabolic activation system. The number of revertant colonies was reduced in the S. typhimurium TA98 strain in the absence of the metabolic activation system and in the S. typhimurium TA100 strain regardless of the presence of the metabolic activation system. However, turbidity and precipitation were not observed in any strain that was incubated with the UG0712 formulation for 48 h. Based on these results, the strain specific dose for the confirmatory test was selected and 2-fold serial dilutions were performed to yield 5 concentration levels. The number of revertant colonies was automatically counted using a colony counter (SINBIOSIS, UK). Results were expressed as the mean number of revertant colonies from triplicate plates per concentration (with standard deviation) and a ratio of the mean concurrent vehicle control value.
**In vitro** chromosome aberration test in Chinese hamster lung (CHL) cells

The *in vitro* chromosome aberration test was performed using the methods described in the OECD and KFDA guidelines [14,17] and based on published methods for cytogenetic tests [18-20]. The Chinese hamster lung (CHL/IU) cell line was purchased from the American Type Culture Collection (ATCC, USA); this cell line is the most frequently used line for the *in vitro* chromosome aberration test for regulatory submission owing to its high detection sensitivity.

A growth inhibition test (MTT assay) [21] was performed to determine the relative toxicity of UG0712 to the cells. In the growth inhibition test, the IC₅₀ was calculated to be 100 µg/mL for the short-term (6-h) and continuous (24-h) treatments in the absence of the metabolic activation system, and calculated to be 800 µg/mL for the short-term (6-h) treatment in the presence of the metabolic activation system. Turbidity and precipitation were not observed at concentrations up to 5000 µg/mL in any treatment group at the beginning or the end of treatment. Using these results, the concentration range chosen for the confirmatory tests was designed with consideration of the cytotoxicity of UG0712. Treatment at each concentration was conducted in duplicate. The slides were prepared according to the hypotonic-methanol-glacial acetic acid-flame drying-giemsa stain method for metaphase plate analysis. At least 200 well-spread intact metaphase cells were scored for each concentration under 1000× magnification by using a differential interference microscope.

For the purposes of chromosome aberration identification, chromosome aberrations were classified into 2 groups: structural aberrations and numerical aberrations. Structural aberrations were subdivided into chromatid breaks (ctb), chromatid exchange (cte), chromosome breaks (csb), and chromosome exchange (cse). Numerical aberrations consisted of polyploidy (pol) only. Two types of aberration, chromatid and chromosome gap, were recorded, but not included in the calculation of the aberration rates. In the metaphase, because there were several gaps or cuttings, aberrations were recorded as fragments (frg). The criteria used to define chromosome aberrations were based on the report of Sofuni et al. [20]. If an appearance rate was less than 5%, between 5 and 10%, or higher than 10%, it was considered to be negative, equivocal, or positive, respectively.

**In vivo** micronucleus test in male mice

The *in vivo* micronucleus test was performed using the methods described in the OECD and KFDA guidelines [14,22] and based on the published methods for cytogenetic tests [23,24]. Specific pathogen-free male mice (IcrTacSam:ICR, 27.86-30.44 g, approximately 7 weeks of age) were obtained from Samtako Bio Korea Inc. (Osan, Korea) and used after 9 days of acclimation. The animals were housed in polycarbonate cages with bedding. An ambient temperature of 21.7-23.6°C, a relative humidity of 47.7-59.9%, an air ventilation rate of 10-15 changes/h, a light intensity of 150-300 lux, and a photoperiod of 12 h were maintained throughout the study. A commercial pellet diet and water were provided *ad libitum*.

The dose range-finding test was performed using 5 dose levels (125, 250, 500, 1,000, and 2,000 mg/kg), the highest of which was the maximum dose for treatment up to 14 days, according to OECD guidelines. After administration, the mice did not show any clinical signs or behavioral alterations during the observation period. The frequencies of micronucleated polychromatic erythrocytes (MNPCEs) did not change for 72 h after dosing in the 2,000 mg/kg group. Based on these results, the *in vivo* micronucleus test was conducted at 3 dose levels (500, 1,000, and 2,000 mg/10 mL/kg). UG0712 was administered by a single oral gavage, whereas the positive control was administered intraperitoneally. All animals were sacrificed by cervical dislocation approximately 24 h after the administration. The micronucleus test was carried out according to the method described by Schmid [24]. Smears were allowed to dry, fixed with methanol, and stained with a 5% giemsa solution for 30 min. The stained slides were washed and allowed to air-dry. Slides were then examined under 1,000× magnification by observers who were blind to the treatments. A total of 2000 polychromatic erythrocytes (PCEs) were scored per animal by the same observer to determine the frequency of MNPCEs. The PCE/(PCE+NCE) ratio, an indicator of cytotoxicity, was calculated by counting 1000 total erythrocytes per animal. The results were judged as positive when there was a statistically significant and dose-related reproducible increase in the frequencies of micronucleated polychromatic erythrocytes for at least 1 dose level.
Statistical analysis
The table of Kastenbaum and Bowman [25] was used to determine if the frequencies of micronucleated polychromatic erythrocytes for individual dose groups significantly increased. The t-test and ANOVA were conducted on the differences in PCE/(PCE+NCE) ratio and body weight change, respectively. Statistical tests were regarded as significant when the P-value was less than 0.05.

Results

Bacterial reverse mutation test
The results of the bacterial reverse mutation test using UG0712 are shown in Figure 1 and Table 1. No contaminant colonies were observed on the sterility plates for the highest concentration of UG0712 and the metabolic activation system. The number of revertant colonies in all strains was not increased more than 2-fold compared to the concurrent vehicle control in the absence or presence of the metabolic activation system. However, indicators of growth inhibition, such as a decrease in the number of colonies compared to that for the concurrent vehicle control, was observed at the 625 µg/plate concentration in the S. typhimurium TA98 and TA100 strains in the absence of the metabolic activation system, and at the 1,250 µg/plate concentration in the S. typhimurium TA100 strain in the presence of the metabolic activation system. Turbidity and precipitation were not observed in any strain regardless of the presence of the metabolic activation system. The positive controls induced significant increases (defined as ≥4 times that of the concurrent vehicle control) in the number of revertant colonies, indicating that the test was valid.

In vitro chromosomal aberration test
The number of metaphase cells with structural and numerical aberrations is presented in Table 2. The number of aberrant metaphase cells at the concentrations of UG0712 tested ranged from 0.5 to 2.0% for the short-term (6-h) treatment in the absence or presence of the metabolic activation system, and from 0.5 to 1.5% for the continuous (22-h) treatment in the absence of the metabolic activation system. Therefore, the number of aberrant metaphase cells was not increased compared with that of the concurrent vehicle control at any concentration, regardless of the presence of the metabolic activation system. The number of aberrant metaphase cells in the positive control group in the absence or presence of the metabolic activation system was 15.5 and 15.5%, respectively, for the short-term treatment, and 15.0% the continuous treatment in the absence of the metabolic activation system, indicating that the test was valid.

In vivo micronucleus test in male mice
No clinical signs or mortality related to UG0712 treatment was observed, and no significant body weight changes were noted during the observation period in any animal. Table 3 shows the frequencies of micronucleated polychromatic erythrocytes per 2000 polychromatic erythrocytes (PCEs) and the ratios of PCEs per 1000 erythrocytes (PCE/[PCE+NCE]), which is an indicator of cytotoxicity. The frequencies of MNPCES were 0.40, 0.40, 0.60, and 0.60, respectively, in the vehicle control, 500, 1,000, and 2,000 mg/kg treatment groups. Therefore, no statistically significant increase in the frequency of micronucleated polychromatic erythrocytes compared to the concurrent vehicle control group was observed at any dose of UG0712. The ratio of PCEs per 1000 erythrocytes (PCE/[PCE+NCE]) in the vehicle control, 500, 1,000, and 2,000 mg/kg treatment groups was 0.48, 0.44, 0.47, and 0.43, respectively, and there were no significant differences between the vehicle control group and the UG0712-treated groups. The frequency of micronucleated polychromatic erythrocytes and the ratio of PCE/(PCE+NCE) in the positive control group was 132.80
and 0.46, respectively, and the frequency of micronucleated polychromatic erythrocytes was significantly increased in comparison to that of the concurrent vehicle control group, indicating that the present study was performed under acceptable experimental conditions, and supporting the validity of the results.

### Discussion

Traditional herbal medicine has developed for several thousand years to maintain the equilibrium of the human body under diseases or stress in the east of Asia including China, Korea and Japan [1, 26-29]. But on the contrary to its effectiveness, the toxicity of herbs used as the traditional medicine has become a major obstacle in clinical application. Traditionally, general toxicities of medicinal herbs are often introduced in ancient literatures. However, there is no information on its genetic studies based on the scientific demonstration.

Ginseng has been used for several thousand years as a traditional herbal medicine to promote longevity, enhance resistance to diseases [1,26-29]. Ginseng root, which is harvested after several years’ cultivation, is used more often than other parts of the ginseng plant such as berry, stem and leaf although ginseng leaf contains similar active ingredients with pharmacological effects and have larger amounts of the same active ingredients than its root [4,11]. The extracts of ginseng leaf have multifaceted pharmacological effects in the central nervous system and a broad range of beneficial effects including anti-fatigue, anti-hyperglycemic, anti-obesity, anti-cancer, anti-oxidant and anti-aging activities.

| Concentration (µg/plate) | Revertant colonies per plate (Plate A, B and C) (Mean±SD) [Factor] | Base substitution type | Frameshift type |
|--------------------------|---------------------------------------------------------------|---------------------|----------------|
|                          | TA100 TA1535 WP2uvrA (pKM101) TA98 TA1537                      |                     |                |
| 0                        | 127, 128, 130 11, 15, 12 119, 106, 108 27, 26, 32 6, 7, 5      | 128±2 13±2 111±7 28±3 6±1 |                |
| 39.1                     | 128, 124, 125 128±2 [1.0] - - 25, 30, 31 29±3 [1.0] -               |
| 78.2                     | 136, 126, 129 130±5 [1.0] - - 27, 29, 27 28±1 [1.0] -               |
| 156.3                    | 127, 126, 126 126±1 [1.0] - - 29, 26, 28 28±2 [1.0] -               |
| 312.5                    | 127, 125, 123 14, 12, 15 109, 105, 125 30, 27, 29 7, 6, 6          |
| 625                      | 96, 84, 76 85±10 [0.7]' 12, 13, 12 110, 126, 110 18, 21, 19 8, 6, 7 |
|                           | 12±1 [0.9] 115±9 [1.0] 19±2 [0.7]' 7±1 [1.2] |                     |                |
| 1250                     | - 12, 13, 15 114, 103, 108 13±2 [1.0] 108±6 [1.0] - 8, 5, 9 | 7±2 [1.2] |                |
| 2500                     | - 13, 15, 15 113, 122, 120 14±1 [1.1] 118±5 [1.1] - 5, 9, 6 | 7±2 [1.2] |                |
| 5000                     | - 11, 17, 15 129, 119, 103 14±3 [1.1] 117±13 [1.1] - 7, 8, 9 | 8±1 [1.3] |                |
| Positive control          | 592, 518, 521 506, 523, 512 723, 704, 707 519, 571, 569 515, 594, 569 |
|                          | 544±42 [4.3] 514±9 [39.5] 711±10 [6.4] 553±29 [19.8] 559±40 [93.2] |

*Number of revertant colonies of the treated plate/number of revertant colonies of the vehicle control plate. -, no data; *, growth inhibition.

---

**Table 1. Results of the bacterial reverse mutation test for UG0712 in the absence of the metabolic activation system**

| Strains Positive control | Concentration (µg/plate) |
|--------------------------|--------------------------|
| TA100 Sodium azide (SA)  | 1.5                      |
| TA1535 Sodium azide (SA) | 1.5                      |
| WP2uvrA(pKM101) 4-Nitroquinoline-1-oxide (4-NQO) | 5.0                |
| TA98 2-Nitrofluorene (2-NF) | 5.0                |
| TA1537 9-Aminoanthracene (9-AA) | 80.0             |
Ginseng berry extract has been reported to show better anti-hyperglycemic activity than ginseng root extract when used at the same concentration [31], and have a higher content of total ginsenosides than its root extract [13]. It was reported that American ginseng berry and leaf extract significantly reduced body weight in adult ob/ob and db/db mice, models of type 2 diabetes [32,33].

Although ginseng plants have been extensively studied for their therapeutic benefits, evidence-based information on the safety of ginseng leaf extract is limited. According to previous reports, the LD_{50} value of ginseng leaf extract was approximately 625 mg/kg when administered to mice by intraperitoneal injection [34], and ginseng leaf extract did not affect blood cell counts, hemoglobin levels, or renal function in a subacute toxicity study [4]. Zhang et al. demonstrated that *Panax ginseng* has no genotoxicity by the comet assay using mouse peripheral lymphocytes [35]. Furthermore, they reported that total saponins from stem and leaf of *Panax ginseng* inhibit...
cyclophosphamide-induced DNA damage and apoptosis in mouse bone marrow cells and peripheral lymphocyte cells, implying anti-clastogenic and anti-oxidant effects of *Panax ginseng* [36].

To investigate the safety of UG0712 ginseng leaf extract, several safety tests were carried out in this study, because no single test can detect every genotoxic effect [37]. The most commonly used method for assessing the genotoxic potential of herbal medicines is the bacterial reverse mutation test in *S. typhimurium* and *E. coli* [38]. The objective of this test is to reveal the mutagenic potential of a test substance in a prokaryote organism and determine whether the reactive metabolite is a product of the metabolic activation system. The number of revertant colonies in *S. typhimurium* (TA98, TA100, TA1535, and TA1537) and *E. coli* (WP2uvrA) strains was not increased in comparison to the concurrent vehicle control or the absence of the metabolic activation system. However, growth inhibition was observed in *S. typhimurium* TA98 and TA100 strains regardless of the presence of the metabolic activation system.

The *in vitro* chromosome aberration (CA) test is a widely used assessment of genotoxicity, because many birth defects and human genetic diseases are associated with abnormal chromosome complements. In the chromosome aberration test, the number of metaphase cells with structural and numerical aberrations was not increased compared with that of the concurrent vehicle control at any concentration, regardless of the presence of the metabolic activation system. Although the current preferred method of staining for the micronucleus (MN) assay is acridine orange staining [39], giemsa stain was found to be acceptable by an international expert group that recently reviewed the *in vivo* rodent erythrocyte micronucleus assay in the International Workshop on Genotoxicity Test Procedures [23]. The time of peak micronuclei induction should be selected as the sacrifice time of the mutants. The frequency of micronucleated polychromatic erythrocytes did not change at 24, 48, and 72 h after administration of 2,000 mg/kg in the dose range-finding test. Based on this information, mice were sacrificed approximately 24 h after dosing. In male mice, a single oral administration of UG0712 at doses up to 2,000 mg/kg did not induce an increase in the frequency of micronucleated polychromatic erythrocytes in the bone marrow.

UG0712 ginseng leaf extract did not cause a mutagenic response in 4 *S. typhimurium* strains or 1 *E. coli* strain, did not induce clastogenicity in the *in vitro* chromosome aberration test using Chinese hamster lung cells, and did not induce an increase in the frequency of micronucleated polychromatic erythrocytes in mouse bone marrow cells. No dose-related increase was observed in any of the parameters measured, suggesting that there were no adverse effects associated with UG0712 treatment. Our results suggest that UG0712 is safe for use in terms of genotoxicity.

### References

1. Attele AS, Wu JA, Yuan CS. Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 1999; 58(11): 1685-1693.
2. Cheng Y, Shen LH, Zhang JT. Anti-amnestic and anti-aging effects of ginsenoside Rg1 and Rb1 and its mechanism of action. Acta Pharmacol Sin 2005; 26(2): 143-149.
3. Shin HR, Kim JY, Yun TK, Morgan G, Vainio H. The cancer-preventive potential of *Panax* ginseng: a review of human and experimental evidence. Cancer Causes Control 2000; 11(6): 565-576.
4. Wang H, Peng D, Xie J. Ginseng leaf-stem: bioactive constituents and pharmacological functions. Chin Med 2009; 4: 20.
5. Cheng TO. *Panax* (ginseng) is not a panacea. Arch Intern Med 2000; 160(21): 3329.
6. Wang Z, Zheng Q, Liu K, Li G, Zheng R. Ginsenoside Rh2(2) enhances antitumour activity and decreases genotoxic effect of cyclophosphamide. Basic Clin Pharmacol Toxicol 2006; 98(4): 411-415.
7. Lee FC. Facts About Ginseng: The Elixir of Life. Hollym International Corporation 1992.
8. Qi X, Igarov S, Luo G, Liang Q, Jun FW, Wang Y, Sutherland I. Preparative isolation and purification of ginsenosides RF, Re, Rd and Rb1 from the roots of *Panax* ginseng with a salt-containing solvent system and flow step-gradient by high performance counter-current chromatography coupled with an evaporative light scattering detector. J Chromatogr A 2010; 1217(13): 1995-2001.
9. Raghavendran HR, Sathyarith B, Shin J, Kim HK, Han JM, Cho J, Son CG. *Panax* ginseng modulates cytokines in bone marrow toxicity and myelopoesis: ginsenoside Rg1 partially supports...
myelopoiesis. PLoS One 2012; 7(4): e33733.
10. Ceylan-Isik AF, Fliethman RM, Wold LE, Ren J. Herbal and traditional Chinese medicine for the treatment of cardiovascular complications in diabetes mellitus. Curr Diabetes Rev 2008; 4(4): 320-328.
11. Hou JP. The chemical constituents of ginseng plants. Comp Med East West 1977; 5(2): 123-145.
12. Zhang QH, Wu CF, Duan L, Yang YJ. Protective effects of total saponins from stem and leaf of Panax ginseng against cyclophosphamide-induced genotoxicity and apoptosis in mouse bone marrow cells and peripheral lymphocyte cells. Food Chem Toxicol 2008; 46(1): 293-302.
13. Xie JT, Mehdendale SR, Wang A, Han AH, Wu JA, Osinski J, Yuan CS. American ginseng leaf: ginsenoside analysis and hypoglycemic activity. Pharmacol Res 2004; 49(2): 113-117.
14. OECD, Guideline for Testing of Chemicals, Section 4, Health Effects, No. 471, 1997b.
15. Ishidate M Jr, Odashima S. Chromosome tests with 134 compounds on Chinese hamster cells in vitro—screening for chemical carcinogens. Mutat Res 1977; 48(3-4): 337-353.
16. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65(1-2): 55-63.
17. OECD, Guideline for Testing of Chemicals, Section 4, Health Effects, No. 473, 1997b.
18. Ishidate M Jr, Data book of chromosomal aberration test in vitro. Elsevier, 1998.
19. Ishidate M Jr, Osadchuk S. Chromosome tests with 134 compounds on Chinese hamster cells in vitro—a screening for chemical carcinogens. Mutat Res 1977; 48(3-4): 337-353.
20. Sofani T, Matsuka M, Sawada M, Ishidate M Jr, Zeiger E, Shelby MD. A comparison of chromosome aberration induction by 25 compounds tested by two Chinese hamster cell (CHL and CHO) systems in culture. Mutat Res 1990; 241(2): 175-213.
21. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65(1-2): 55-63.
22. OECD, Guideline for Testing of Chemicals, Section 4, Health Effects, No. 474, 1997c.
23. Hayashi M, MacGregor JT, Gatehouse DG, Adler ID, Blakey DH, Dertinger SD, Krishna G, Morita T, Russo A, Satou S. In vivo rodent erythrocyte micronucleus assay. II. Some aspects of protocol design including repeated treatments, integration with toxicity testing, and automated scoring. Environ Mol Mutagen 2000; 35(3): 234-252.
24. Schmid W. The micronucleus test. Mutat Res 1975; 31(1): 9-15.
25. Kastenbaum MA, Bowman KO. Tables for determining the statistical significance of mutation frequencies. Mutat Res 1970; 9(5): 527-549.
26. Abdelmigid HM, New Trends in genotoxicity testing of herbal medicinal plants, New Insights into Toxicity and Drug Testing, Dr. Sivakumar Gowder (Ed.), 2013. (ISBN: 978-953-51-0946-4, InTech, DOI: 10.5772/54858. Available from: http://www.intechopen.com/books/new-insights-into-toxicity-and-drug-testing/new-trends-in-genotoxicity-testing-of-herbal-medicinal-plants).
27. Tinwell H, Asby J. Comparison of acridine orange and Giemsa stains in several mouse bone marrow micronucleus assays—including a triple dose study. Mutagenesis 1989; 4(6): 476-481.